Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent High Grade B-Cell Lymphoma: early-phase trial registry
5 of 8 indexed Recurrent High Grade B-Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Recurrent High Grade B-Cell Lymphoma: 8 US clinical trials tracked, 5 recruiting.
Recurrent High Grade B-Cell Lymphoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Sumithira Vasu, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-high-grade-b-cell-lymphoma
OPEN 5 | RECR 63% | LATE 0 | EARLY 7 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Recurrent High Grade B-Cell Lymphoma lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent High Grade B-Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent High Grade B-Cell Lymphoma is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Recurrent High Grade B-Cell Lymphoma trials is spread across many organizations.
Sumithira Vasu accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent High Grade B-Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 8 trials that report a genuine target (sentinel values excluded). 8 of those (100%) plan for fewer than 100 participants.
-
Recurrent High Grade B-Cell Lymphoma research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Sumithira Vasu
NCT05418088
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT05672251
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
NCT07098364
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
NCT06784726
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
NCT05077527
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
NCT05507541
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
NCT04409314
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
NCT03309878
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent High Grade B-Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent High Grade B-Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent High Grade B-Cell Lymphoma page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Recurrent High Grade B-Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sumithira Vasu sponsors the most Recurrent High Grade B-Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Sumithira Vasu's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent High Grade B-Cell Lymphoma condition card totals 8 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.